GlobeNewswire

Active Biotechs partner NeoTX kommer stå som värd för ett KOL-webbseminarium om att övervinna resistens mot checkpoint-hämmare

Dela

Lund 8 juli 2021 - Active Biotech (Nasdaq Stockholm: ACTI) lämnade idag  information om att samarbetspartner i naptumomab-projektet, NeoTX, kommer att vara värd för ett webbseminarium för key opinion leaders (KOL) om att övervinna resistens mot cancerbehandling med checkpoint-hämmare. Seminariet avhålls onsdagen den 14 juli klockan 10 amerikansk östkusttid (ET).

Webbseminariet kommer att innehålla en presentation av den kliniska experten Mario Sznol, MD, Yale Cancer Center, som kommer att diskutera ”New Frontiers for Checkpoint Inhibitors in Immuno-Oncology”. NeoTXs ledning kommer också att ge en uppdatering kring sin ledande läkemedelskandidat naptumomab estafenatox (naptumomab) från den tumörriktade superantigen (TTS)-plattformen, om att övervinna resistens. Naptumomab utvärderas i kombination med kemoterapi, checkpoint-hämmare och CAR T. Dr. Sznol och NeoTX ledning kommer att vara tillgängliga för att svara på frågor efter de formella presentationerna.

Se även neotx.com/press-releases för NeoTXs kommunikation relaterad till evenemanget och för registrering till webbseminariet.

Active Biotech har sedan 2016 ett avtal med NeoTX Therapeutics Ltd. gällande global utveckling och kommersialisering av naptumomab för behandling av cancer.

För ytterligare information, vänligen kontakta:
Helén Tuvesson, VD, 046 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, 046 19 20 44, hans.kolam@activebiotech.com

Denna information lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 8 juli 2021, kl. 08.30.

Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) är ett bioteknikföretag som använder sin omfattande kompetensbas och projektportfölj för att utveckla unika immunmodulerande behandlingar för specialiserade onkologi- och immunologiska indikationer med stort medicinskt behov och betydande kommersiell potential. Efter beslut om en ny inriktning av forsknings- och utvecklingsverksamheten syftar Active Biotechs affärsmodell till att driva projekt till klinisk utvecklingsfas för att sedan vidare-utveckla dessa internt eller i externa partnerskap. Active Biotech har för närvarande tre projekt i projektportföljen: Naptumomab, som utvecklas i samarbete med NeoTX Therapeutics, är en tumörriktad immunterapi. Ett kliniskt fas Ib/II-program i patienter med avancerade solida tumörer pågår. Tasquinimod och laquinimod, som är immunomodulerande småmolekyler med en verknings-mekanism som innefattar modulering av funktionen hos myeloida immunceller, avses att användas för behandling av hematologiska cancerformer respektive inflammatoriska ögonsjukdomar. Tasquinimod är i klinisk fas Ib/IIa för behandling av multipelt myelom. En klinisk fas II för behandling av patienter med icke-infektiös uveit med laquinimod förbereds och planeras starta under andra halvåret 2021. Besök www.activebiotech.com för mer information.

(Org.nr 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: 046 19 20 00

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Summary of AB Klaipedos nafta webinar29.7.2021 11:30:00 CEST | Press release

On the 29th July 2021, AB Klaipedos nafta (KN) held an investor conference webinar where KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė commented Company’s financial results for the six months of 2021. Webinar recording is available online at: https://youtu.be/BmHfUpOVmEM The presentation demonstrated during the webinar is attached to this announcement. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2

Correction: AB Klaipėdos nafta financial information reporting dates in 202129.7.2021 10:15:00 CEST | Press release

Correction: AB Klaipedos nafta interim financial information for the 6 months of 2021 has been released on 29 July 2021. AB Klaipėdos nafta (further – KN) informs that it plans to release financial information in 2021 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2021KN preliminary revenues for the previous month29 January 2021Interim financial information for the year 20207 April 2021Audited financial statements for the year 202030 April 2021Interim financial information for the 1st quarter of 20218 June 2021Social responsibility report for the year 202029 July 2021Interim financial information for the 6 months of 202129 October 2021Interim financial information for the 3 quarters of 2021 On 30 April 2021, the Company plans to convene an Ordinary General Meeting of Shareholders. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276.

Hexagon Digital Wave signs new equipment and service agreement with Linde29.7.2021 09:00:00 CEST | Press release

Hexagon Digital Wave, a business of Hexagon Composites has signed an agreement with Linde, a leading industrial gas and engineering company. The agreement covers the supply and service of Ultrasonic Examination (UE) testing equipment. The estimated total value of the agreement is USD 2 million (approx. NOK 17 million) and designates Hexagon Digital Wave as a long-term partner. Driving energy transformation “We are excited to extend our relationship with the great team at Linde”, says Keith Fountain, UE international Sales Manager Hexagon Digital Wave. “Over the past 14 years we have provided our equipment to one of the market leaders in the industrial gas environment and helped to improve the safety of their cylinders.” About the market The non-destructive UE test and process enables the recertification of the cylinders without removing the internal product which improves the safety and allows a number of ESG requirements to be accomplished. Positive environmental impacts are accomplis

Nexstim Receives an NBS System Order from a University Hospital in Germany29.7.2021 09:00:00 CEST | Press release

Press release, Helsinki, 29 July 2021 at 10 AM(EEST) Nexstim Receives an NBS System Order froma University Hospital in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS System order in Germany. The customer is a German university hospital and a new customer for Nexstim. Nexstim NBS systems with SmartFocus® nTMS technology are mainly used for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumor’s or other lesion’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. Mikko Karvinen, CEO of Nexstim commented: “We are very happy about our continued success in expanding our NBS presence within the German university hospitals. This sale is a good start t

GeoJunxion NV (ticker: GOJXN.AS) Formerly called AND International Publishers NV (AND.AS) Publishes its July 2021 Trading Update29.7.2021 08:30:00 CEST | Press release

Capelle aan den Ijssel, The Netherlands 29 July 2021 - GeoJunxion significantly increases order intake and shows encouraging Q2 and 1H2021 YoY topline growth. Looking back at the first half of 2021 and more specifically at the second quarter, Covid-19 and its related measures are still proving to be a significant challenge for the global economy. However, the GeoJunxion team and our underlying business continued to show strong resilience and improved performance during Q2: Revenue during the past quarter has grown by 30% compared to the same quarter in 2020. For the first half of 2021, revenue increased by 20% compared to the same period last year. Thanks to an extraordinary Q2 performance, our order intake for the first half of 2021 doubled compared to the same period last year. We are continuously encouraged by the market response regarding our new premium location aware products and intelligence location services, which have resulted in the increased strength of our pipeline. It is

AB Klaipėdos nafta holds a Webinar regarding unaudited financial results for the six months of 202129.7.2021 08:00:00 CEST | Press release

On the 29th of July 2021 at 9:00 (EET) AB Klaipėdos nafta (hereinafter – the Company) holds a conference webinar for its shareholders, investors, mass media representatives and other stakeholders. The presentation is held in English. The webinar is hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who introduces the Company’s financial results for the six months of 2021 and will answer the participant questions. Webinar presentation is enclosed. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2

AB Klaipėdos nafta unaudited financial information regarding the six months of 202129.7.2021 07:55:00 CEST | Press release

AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the six months ended 30 June 2021. Main financial indicators of the Group comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021 Change, compared to 6 months of 2020Revenue31.6 million EUR- 22.4%31.6 million EUR- 22.4%Net profit (loss)- 6.8 million EUR- 16.2 million EUR- 0.2 million EUR- 7.5 million EUREBITDA14.6 million EUR- 39.7%14.6 million EUR- 39.7% Main financial indicators of the Company comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021Change, compared to 6 months of 2020Revenue30.1 million EUR- 24.2%30.1 million EUR- 24.2%Net profit (loss)- 7.2 million EUR- 16.5 million EUR-0.7 million EUR- 7.9 million EUR EBITDA14.0 million EUR- 41.7%14.0 mi